[1]杜 佳.2018年~2019年杭州某医院肺炎克雷伯菌耐药性分析[J].医学信息,2021,34(10):153-155.[doi:10.3969/j.issn.1006-1959.2021.10.044]
　DU Jia.Analysis of the Resistance of Klebsiella Pneumoniae in a Hospital in Hangzhou from 2018 to 2019[J].Medical Information,2021,34(10):153-155.[doi:10.3969/j.issn.1006-1959.2021.10.044]
点击复制

2018年~2019年杭州某医院肺炎克雷伯菌耐药性分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年10期
页码:
153-155
栏目:
调查分析
出版日期:
2021-05-15

文章信息/Info

Title:
Analysis of the Resistance of Klebsiella Pneumoniae in a Hospital in Hangzhou from 2018 to 2019
文章编号:
1006-1959（2021）10-0153-03
作者:
杜 佳
（1.中国科学院大学附属肿瘤医院/浙江省肿瘤医院检验科，浙江 杭州 310000；2.中国科学院基础医学与肿瘤研究所，浙江 杭州 310022）
Author(s):
DU Jia
(1.Cancer Hospital of University of Chinese Academy of Sciences/Department of Laboratory Medicine,Zhejiang Cancer Hospital,Hangzhou 310000,Zhejiang,China;2.Institute of Basic Medicine and Cancer,Chinese Academy of Sciences,Hangzhou 310022, Zhejiang,China)
关键词:
肺炎克雷伯菌; 细菌耐药; 药敏试验
Keywords:
Klebsiella pneumoniae; Bacterial resistance; Drug susceptibility test
分类号:
R446.5
DOI:
10.3969/j.issn.1006-1959.2021.10.044
文献标志码:
A
摘要:
目的 回顾性分析某医院肺炎克雷伯菌的耐药现状，为临床治疗提供指导建议。方法 收集某三甲医院2018年~2019年784株肺炎克雷伯菌，统计标本来源，采用VITEK 2Compact全自动微生物分析仪对菌株进行鉴定和药敏试验，手工药敏试验采用K-B法，分析该院肺炎克雷伯菌耐药情况。结果 784株肺炎克雷伯菌主要来源于痰液标本（50.51%）、其次是血液标本（15.22%）、尿液标本（13.91%），其他标本包括伤口、胆汁、排泄物、腹腔引流液、留置管和脓肿等（20.36%）；2018年~2019年该院肺炎克雷伯菌总体耐药情况呈缓慢上升趋势；头孢菌素类药物中，对头孢唑林（46.82%）和头孢曲松（44.15%）耐药率较高，对头孢他啶（32.75%）、头孢吡肟（27.65%）和头孢替坦（22.05%）耐药率较低；碳青霉烯类药物中，对亚胺培南（24.05%）和美罗培南（23.00%）的耐药率较高，对厄他培南的耐药率较低（14.95%）；氨基糖苷类药物中，对阿米卡星（17.75%）、庆大霉素（28.15%）和妥布霉素（21.75%）的耐药率较低，对环丙沙星（33.85%）和左氧氟沙星（33.10%）耐药率较高；未检出对替加环素耐药的肺炎克雷伯菌。结论 该院分离的肺炎克雷伯菌的感染类型多样化，耐药情况较严重，呈缓慢上升趋势，并没有出现某些药物耐药率下降现象，因此应加大力度整治抗生素滥用现象。
Abstract:
Objective To retrospectively analyze the current status of drug resistance of Klebsiella pneumoniae in a hospital and provide guidance and recommendations for clinical treatment.Methods Collecting 784 strains of Klebsiella pneumoniae from 2018 to 2019 in a tertiary hospital, and count the source of the specimens. The VITEK 2Compact automatic microbial analyzer was used to identify the strains and test for drug sensitivity.K-B method was used in manual drug susceptibility test to analyze the drug resistance of Klebsiella pneumonia in the hospital.Results 784 strains of Klebsiella pneumoniae were mainly derived from sputum specimens (50.51%), followed by blood specimens (15.22%), urine specimens (13.91%), and other specimens including wounds, bile, excreta, abdominal drainage,indwelling tube and abscess, etc. (20.36%);From 2018 to 2019, the overall resistance of Klebsiella pneumoniae in the hospital showed a slow upward trend;Among cephalosporins, the resistance rate to cefazolin (46.82%) and ceftriaxone (44.15%) was higher.Low resistance rate to ceftazidime (32.75%), cefepime (27.65%) and cefotetan (22.05%);Among carbapenem drugs, the resistance rate to imipenem (24.05%) and meropenem (23.00%) was higher, and the resistance rate to ertapenem was lower (14.95%);Among the aminoglycoside drugs, the resistance rate to amikacin (17.75%), gentamicin (28.15%) and tobramycin (21.75%) was low, and the resistance rate to ciprofloxacin (33.85%) and Levofloxacin (33.10%) had a higher resistance rate;Klebsiella pneumoniae resistant to tigecycline was not detected.Conclusion The infection types of Klebsiella pneumoniae isolated from this hospital are diversified, and the drug resistance is relatively serious, showing a slow upward trend. There is no decline in the drug resistance rate of certain drugs. Therefore, we should increase efforts to rectify the abuse of antibiotics.

参考文献/References:

[1]Chong Y,Shimoda S,Shimono N.Current epidemiology,genetic evolution and clinical impact of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae[J].Infection,Genetics and Evolution,2018(61):185-188.[2]卢峰,卜素,张昌峰,等.肺炎克雷伯菌的临床分布特征及耐药性分析[J].临床肺科杂志,2020,25(9):1329-1332.[3]王瑞华,冯贺强,王玮,等.血流感染患者产超广谱β-内酰胺酶大肠埃希菌和肺炎克雷伯菌耐药性及危险因素分析[J].中国抗生素杂志,2020,22(12):1262-1267.[4]谢清,周颖,孔妍,等.产超广谱β-内酰胺酶大肠埃希菌和肺炎克雷伯菌血流感染的危险因素分析[J].中国医院用药评价与分析,2020,2(9):1142-1145,1149.[5]白佳玉,王琦.耐碳青霉烯类肺炎克雷伯菌耐药性及临床特征分析[J].中国实用医药,2020,3(34):199-202.[6]宋晓超,乔美珍,赵丽娜,等.重症监护室与普通病房碳青霉烯类耐药肺炎克雷伯菌感染与耐药性分析[J].中华医院感染学杂志,2020,5(22):3372-3377.[7]Walkty A,DeCorby M,Nichol K,et al.In vitro activity of colistin(polymyxin E)against 3,480 isolates of gram-negative bacilli obtained from patients in Canadian hospitals in the CANWARD study, 2007-2008[J].Antimicrobial Agents and Chemotherapy,2009,53(11):4924-4926.[8]张雅薇,王辉.2015年CLSI M100-S25主要更新内容介绍[J].中华检验医学杂志,2015,38(4):229-232.[9]Shon AS,Bajwa RP,Russo TA,et al.Hypervirulent(hypermucoviscous)Klebsiella pneumoniae:a new and dangerous breed[J].Virulence,2013,4(2):107-118.[10]Liu YM,Li BB,Zhang YY,et al.Clinical and molecular characteristics of emerging hypervirulent Klebsiella pneumoniae bloodstream infections in mainland China[J].Antimicrobial Agents and Chemotherapy,2014,58(9):5379-5385.[11]徐安,卓超,苏丹虹,等.2005-2014 年 CHINET 克雷伯菌属细菌耐药性监测[J].中国感染与化疗杂志,2016(16):267-274.[12]Chen Z,Niu H,Chen G,et al.Prevalence of ESBLs-producing Pseudomonas aeruginosa isolates from different wards in a Chinese teaching hospital[J].International Journal of Clinical and Experimental Medicine,2015,8(10):19400-19405.[13]Zandi H,Tabatabaei SM,Ehsani F,et al.Frequency of Extended-Spectrum Beta-lactamases(ESBLs)in strains of Klebsiella and E. coli isolated from patients hospitalized in Yazd[J].Electronic Physician,2017,9(2):3810-3815.[14]Zhang R,Dong N,Huang Y,et al.Evolution of tigecycline-and colistin-resistant CRKP(carbapenem-resistant Klebsiella pneumoniae)in vivo and its persistence in the GI tract[J].Emerging Microbes&Infections,2018,7(1):127.[15]Liu P,Li X,Luo M,et al.Risk Factors for Carbapenem-Resistant Klebsiella pneumoniae Infection:A Meta-Analysis[J].Microb Drug Resist,2018,24(2):190-198.

相似文献/References:

[1]刘永瑞,张 妍,李秀英.肺炎克雷伯菌AmpC酶检测及抗生素选择[J].医学信息,2019,32(19):122.[doi:10.3969/j.issn.1006-1959.2019.19.039]
　LIU Yong-rui,Zhang Yan,LI Xiu-ying.Klebsiella Pneumoniae AmpC Enzyme Detection and Antibiotic Selection[J].Medical Information,2019,32(10):122.[doi:10.3969/j.issn.1006-1959.2019.19.039]
[2]韦海峰.某院微生物检验和细菌耐药性监测的分析[J].医学信息,2020,33(11):134.[doi:10.3969/j.issn.1006-1959.2020.11.042]
　WEI Hai-feng.Analysis of Microbial Testing and Bacterial Resistance Monitoring in a Hospital[J].Medical Information,2020,33(10):134.[doi:10.3969/j.issn.1006-1959.2020.11.042]
[3]周晓玲,张嘉文,陈惠霞.2018-2020年某三甲医院肺炎克雷伯菌的分布情况及耐药现状分析[J].医学信息,2022,35(20):114.[doi:10.3969/j.issn.1006-1959.2022.20.030]
　ZHOU Xiao-ling,ZHANG Jia-wen,CHEN Hui-xia.Analysis of Distribution and Drug Resistance of Klebsiella Pneumoniae in A Tertiary Hospital from 2018 to 2020[J].Medical Information,2022,35(10):114.[doi:10.3969/j.issn.1006-1959.2022.20.030]
[4]陆 颖,朱志军,朱 梅.肺炎克雷伯菌的耐药性及其与生物膜形成的关系[J].医学信息,2021,34(13):65.[doi:10.3969/j.issn.1006-1959.2021.13.017]
　LU Ying,ZHU Zhi-jun,ZHU Mei.Drug Resistance of Klebsiella Pneumoniae and Its Relationship with Biofilm Formation[J].Medical Information,2021,34(10):65.[doi:10.3969/j.issn.1006-1959.2021.13.017]

更新日期/Last Update: 1900-01-01